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SUMMARY
INTRODUCTION: The main extra-hepatic manifestation of hepatitis C is mixed cryoglobulinemia (MC). The aim of this
study was to evaluate its prevalence among patients with chronic hepatitis C (CHC), to correlate its presence to host and virological
variables and to the response to combined therapy with interferon-alpha and ribavirin. CASUISTIC AND METHODS: 202 CHC
naive patients (136 with chronic hepatitis and 66 with cirrhosis) were consecutively evaluated for the presence of cryoglobulins.
Cryoprecipitates were characterized by immunoelectrophoresis and classified according to the Brouet’s criteria. RESULTS: The
prevalence of MC was 27% (54/202), and 24% of them (13/54) showed major clinical manifestation of the disease. Even though
type III MC was more frequent (78%), symptomatic MC was more common in type II MC. The presence of cirrhosis (RR = 2.073;
IC95% = 1.029 - 4.179; p = 0.041), and age of the patients (RR = 1.035; IC95% = 1.008 - 1.062; p = 0.01) were independently
associated with the presence of cryoglobulins. No relationship was found with viral load and genotype. 102 patients were treated
with interferon alpha and ribavirin. Among these, 31 had MC. Sustained virological response (around 30%) was similar in patients
with and without MC (p = 0.971). CONCLUSION: MC represents a prevalent complication in patients with CHC, specially older
and cirrhotic patients. Only 24% of these patients show clinical manifestation of the disease, specially those with type II MC. The
presence of MC did not affect the response to therapy.
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INTRODUCTION
The main extra-hepatic complication caused by hepatitis C virus
(HCV) infection is cryoglobulinemia26 . The prevalence of
cryoglobulinemia in chronic hepatitis C has been highly variable in
different studies, showing frequencies ranging from 2% to 66%17,29.
Even in the series where the frequency of cryoglobulinemia were high,
only in a few cases major manifestations of the disease could be found,
such as purpura; glomerulonephritis; neuropathy, and arthropathy, all
of them resulting from skin and peripheral nerve vasculitis10,15,17,36.
Different studies in the literature report a great variation regarding
prevalence and type of cryoglobulinemia in hepatitis C, besides
variations in the relationship between the cryoprecipitate composition
and the clinical manifestations of the syndrome. These variations have
been attributed to methodological aspects, geographic factors, and
selection criteria of the patients10,15,17,36.
A meta-analysis17, found a relationship between cryoglobulinemia
and the presence of cirrhosis, suggesting that cryoglobulinemia may
be related to the progression of the hepatic disease caused by the
hepatitis C virus.
The presence of cryoglobulinemia did not appear to influence the
response of the hepatitis C treatment when only interferon alpha was
utilized8,24,28. However, the therapeutic response to the combined
treatment of interferon and ribavirin has only been evaluated in the re-
treatment of non-responsive cases to a previous monotherapy
treatment6,8,22, or in specific studies of complications of
cryoglobulinemia, such as vasculitis or glomerulonephritis1,4,5,27,37.
The objectives of this study were to determine the prevalence of
cryoglobulinemia in a group of patients with chronic hepatitis caused
by the C virus and to correlate its presence with demographics and
clinical variables of the host, cryoprecipitate characteristics, variables
related to the virus, and the stage of the hepatic disease. In addition,
the impact of the presence of cryoglobulinemia on the response to the
treatment with interferon alpha and ribavirin was also evaluated.
CASUISTIC AND METHODS
This study evaluated 202 consecutive “naive” patients with chronic
hepatitis C characterized by the presence of positive anti-HCV and
HCV-RNA in the serum. Patients co-infected with the hepatitis B and
HIV; with active alcohol consume (alcohol consumption greater than
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40 g/day) and with autoimmune hepatitis or other chronic hepatic
diseases were excluded.
Aspartate-aminotransferase (AST) and alanine-aminotransferase
(ALT) serum concentrations were determined through an automatic
kinetic method. The genotype of the HCV-RNA was identified through
restriction analysis of the amplified sequences of the non-coding 5’
region. The viral load was determined by the quantitative PCR method
(Amplicor Monitor®, Roche Diagnostics).
One-hundred-eighty-one out of 202 patients were submitted to liver
biopsy, while the remaining 21 patients showed clinical,
ultrasonography and endoscopy signs compatible with cirrhosis and
due to alterations in their blood clotting ability, liver biopsy was not
performed. The biopsy fragments were stained with hematoxylin and
eosin (HE), Masson’s trichrome and reticulin, and the disease stage
was determined according to the presence or absence of hepatic
cirrhosis18.
Determination and characterization of the cryoprecipitates: Blood
samples were collected under appropriated conditions and stored at
4 oC for seven days. After separating the cryoprecipitates by
centrifugation, its concentration was estimated by the Lowry method16.
Samples with concentrations greater than 80 µg/dL were considered
positive and the precipitates were characterized immunologically
through agarose gel immunoelectrophoresis utilizing specific antisera
(anti-IgG, anti-IgA, anti-IgM, anti-κ, and anti-λ). Cryoglobulinemias
were classified according to the criteria described by BROUET et al.3.
Patients with chronic hepatitis C that agreed to receive treatment,
signed an informed consent form and received interferon alpha 3MU
subcutaneously, three times a week and 1.0 to 1.25 g of ribavirin/day
for 24 or 48 weeks, according to established criteria32. Results were
analyzed based upon the “intention-to-treat” basis and sustained
virologic response (SVR) was indicated by undetectable levels of HCV-
RNA in the peripheral blood 24 weeks after stopping the treatment.
Variables analyzed: The following variables related to the presence
of cryoglobulinemia were analyzed: gender; age; route of infection
(parental vs non-parental); genotype and viral load; ALT levels, platelet
count and presence or absence of cirrhosis.
The presence of signs and clinical symptoms associated with
cryoglobulinemia were correlated to age; gender; genotype and HCV
viral load; ALT levels; presence of cirrhosis and type of cryoglobulins.
Data were evaluated with the Student t test and the χ2 test. The
demographic, virological, and histological variables were submitted
to logistic regression to identify independent variables associated with
the presence of cryoglobulins and factors associated with the response
to interferon alpha and ribavirin treatment. The level of significance
considered was 0.05 (5%)13.
RESULTS
Fifty-four (27%) patients were positive for the presence of
cryoglobulins. When comparing subjects with and without cryoglobulins,
the positive cases showed older age (55.1 ± 1.8 y vs 47.6 ± 1.2 y; p <
0.001), and there was no preference for gender. The groups did not differ
on the form of acquiring the infection, viral load and genotype. Among
the 54 patients with cryoprecipitates, 28 (52%) presented cirrhosis; but
this histological finding was present only in 26% of those 148 patients
negatives for cryoglobulins (p = 0.001, Table 1).
Logistic regression for the demographic, histological, and
virological parameters showed that the presence of hepatic cirrhosis
and the age of the subjects were the only two independent variables
associated with the presence of cryoglobulinemia (Table 2).
Table 1
Demographic, histological, and virological characteristics of the hepatitis C carriers with and without cryoglobulinemia
Negative (n = 148) Positive (n = 54) p
Male gender (%) 84 (57%) 26 (48%) 0.354
Age (years) 47.6 ± 1.2 55.5 ± 1.8 < 0.001*
Parenteral route of infection (%) 101 (68%) 31 (57%) 0.206
ALT (x ULN) 2.7 ± 0.2 2.6 ± 0.2 0.777
Genotype 1 (%) 95 (64%) 33 (61%) 0.813
Viral load > 850.000 UI/mL (%) 73 (49%) 26 (48%) 0.991
Cirrhosis (%) 39 (26%) 26 (48%) 0.001*
Age, platelets, and ALT with values expressed as mean ± standard deviation. ULN = upper limit of normality.
Table 2
Factors independently associated with the presence of cryoglobulinemia in patients with chronic hepatitis C
Relative risk IC 95% p
Age 1.035 1.008 - 1.062 0.010
Cirrhosis 2.073 1.029 - 4.179 0.041
Gender, age, genotype, amount of virus, stage and form of infection were included in the regression analysis.
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The analysis of the cryoglobulinemic patients (n = 54) showed
that in 13 of them (24%) major clinical manifestations of the disease
were present. Vasculitis, with or without purpura, was the most prevalent
symptom (10/13), followed by peripheral neuropathy (4/13);
glomerulonephritis (3/13), and arthritis, pancreatitis and Sjögren (1/
13 each). A low degree of B-cell Lymphoma was found in two subjects
that had mixed cryoglobulinemia (MC).
According to the classification of BROUET et al.3, all patients had
mixed cryoglobulinemia (MC): 42/54 (78%) had type III, while 12/54
(22%) showed type II cryoglobulinemia. Major clinical manifestations
were more frequently found among patients with type II cryoglobulinemia
with only two of such patients being asymptomatic. These patients, with
or without clinical manifestations, did not differ biochemically or
hematologically, and were not different for characteristics related to the
virus or the degree of histological lesions (Table 3).
Treatment with interferon alpha and ribavirin: A total of 102
subjects were treated with interferon alpha and ribavirin, of which 31
(30%) were positive for cryoglobulinemia. Before treatment the groups
did not differ regarding demographics and histological data and
virological characteristics (Table 4). The sustained virological response
was similar between both groups (31% vs 29%).
Among the 31 subjects with cryoglobulins, eight symptomatic cases
were treated. All patients had vasculitis, associated with glomerulo-
nephritis in one case, and with peripheral neuropathy in three. Vasculitis
was not detected during the treatment and the levels of cryoglobulins
were reduced or eliminated in seven patients. Neurological symptoms
became worse in two patients during treatment. The response index of
these patients was 25% and did not differ statistically from that found
for the asymptomatic patients (30%).
DISCUSSION
Mixed cryoglobulinemia is relatively common in patients with
chronic C hepatitis, with an average prevalence of 30%10,15,17,26,29,36, but
with a wide variation from 2% to 66%, according to the casuistic
studied7,29.
Methodological and geographic variations as well as the degree of
hepatic damage have been indicated as causes for these discre-
pancies10,15,36. However, since the methodology applied for cryoglobulin
detection is uniform in almost all studies30, it is not likely that
methodological difficulties are influencing these results. On the other
hand, as is evident in almost all studies conducted, the frequency of
cryoglobulinemia is directly correlated with the prevalence of patients
with cirrhosis in the evaluated population10,15,17,21,30,33.
The importance of geographic variations15 could be stressed not
only by the observed differences in the prevalence but also by the type
of cryoglobulin found in the cryoprecipitate in different studies10,12,17,20,31.
Table 4
Demographics, virological, and histological characteristics, and index of response observed in patients with and without mixed cryoglobulinemia treated with INF-
alpha and ribavirin
Cryoglobulin – (n = 71) Cryoglobulin + (n = 31) p
Age (year) 49.6 + 1.6 54.8 + 2.3 0.108
Male Gender (%) 43 (60%) 16 (52%) 0.533
Parenteral route of infection (%) 51 (72%) 18 (58%) 0.256
Genotype 1 (%) 41 (58%) 20 (64%) 0.673
Viral load > 850000 UI/L (%) 42 (59%) 19 (61%) 0.986
Cirrhosis (%) 45 (63%) 17 (55%) 0.554
SVR 22 (31%) 9 (29%) 0.971
SVR - sustained virological response
Table 3
General characteristics, mean values of ALT, genotype, viral load, presence of cirrhosis and type of cryoglobulin presented by the cryoglobulinemic patients with
and without signs/symptoms of the syndrome
Asymptomatics (n = 41) Symptomatics (n = 13) p
Male gender (%) 20 (49%) 6 (46%) 0.878
Age (year) 54.5 ± 2.2 58.4 ± 2.9 0.369
ALT (x LSN) 2.7 ± 1.7 1.9 ± 0.9 0.141
Genotype 1 (%) 21 (51%) 10 (77%) 0.190
Viral load > 800 000 UI/mL) 20 (49%) 6 (46%) 0.878
Cirrhosis (%) 21 (51%) 5 (38%) 0.629
Cryoglobulin type (II : III) 2:39 10:3 < 0.001
ALT- alanine-aminotransferase; Values expressed as mean ± standard deviation.
70
PARISE, E.R.; OLIVEIRA, A.C.; FERRAZ, M.L.; PEREIRA, A.B. & LEITE, K.R. - Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha
and ribavirin. Rev. Inst. Med. trop. S. Paulo, 49(2): 67-72, 2007.
In our study, and corroborating some studies previously
conducted10,17,20, a correlation between the presence of cryoglobulinemia
and the age of the patient was found. The regression analysis shows
that the age factor does not depend on the presence of cirrhosis and
suggests that older patients would be more susceptible to develop this
complication. This correlation adds a new variable to be evaluated in
the studies of MC prevalence in hepatitis C. On the other hand, the
correlation with cirrhosis raises the question wheter MC is a cause or
consequence of cirrhosis. SIAGRIS et al.35 in logistic regression analysis
identified staging score as the only independent variable associated
with cryoglobulinemia, what could suggest that cryoglobulinemia
results in more rapid hepatic fibrosis in HCV infected patients.
No relationship could be found between the presence of MC and
viral load and genotype, although at least in one published paper,
patients with HCV 2c genotype were at higher risk for the development
of extrahepatic manifestations34.
Considering the classification according to BROUET et al.3, the
polyclonal type (type III) was the most prevalent cryoglobulin found
(78% of the patients). Major signs and symptoms related to the presence
of cryoglobulin occurred in 24% of the positive subjects, resulting in a
6% overall prevalence of symptomatic cryoglobulin for all of the
patients evaluated. Among the symptomatic patients, the type II
cryoglobulin was significantly more prevalent (77%). These findings
corroborate with previous data by other authors that also found a greater
frequency of the type II between the patients with symptomatic
cryoglobulin and a greater prevalence of the type III among carriers of
chronic hepatitis C10,17.
Regarding the symptoms, the cryoglobulinemic syndrome included
only those that most correlated with the deposition of immuno-
complexes in the different organs. General symptoms, mainly weakness
and arthralgy, were excluded because they are non-specific for the
cryoglobulinemic syndrome according to other studies2. Therefore, it
was frequent to find more than one sign or symptom in each of the
patients evaluated, and vasculitis was the most frequent sign observed
in this study. The inclusion of lymphoma as a manifestation of
cryoglobulin was considered since a low degree of lymphoma activity
is frequently found in these patients9,11,14. Although such association is
not widely accepted7, in a recent published retrospective and multicenter
Italian study with 1,255 patients with MC25, found that the overall risk
of non Hodgkin lymphoma in patients with MC is about 35 times higher
than in the general population. Anyhow, the hematological
manifestation was not the only clinical signs observed in the cases
included in this study, since lymphoma and vasculitis with purpura
were found in both cases.
Because of the relationship between hepatitis C and cryoglobulin,
the management of the viral infection has been the therapy of choice
for treating symptomatic or asymptomatic cryoglobulinemia. Several
studies in the literature did not show any difference in the response to
the therapy using interferon alpha, among patients with and without
cryoglobulins8,12,24,28,31. However, the introduction of ribavirin as a
therapy option for hepatitis C, modified considerably the therapeutic
response observed for patients of this disease, thus requiring a revision
of the response-associated factors to the treatment30. The majority of
studies that deal with the treatment of these patients with combined
therapy refer to case studies or treatment-groups of symptomatic
patients co-treated with corticosteroids and plasmapheresis. Some of
these reports also studied patients that did not respond to or were
relapsers to a previous monotherapy with interferon alpha, which most
likely does not anticipate the response of subjects not previously
treated1,4,5,6,22,27,37.
Among 202 patients studied, 102 completed treatment with
interferon and ribavirin. In 31 patients with cryoglobulin treated with
interferon and ribavirin, the response was similar to that observed in
71 patients negative for cryoglobulins in this study, and the SVR was
around 30% in both cases, as described in other studies3,12,19,33.
Moreover, in this study, no differences were found between
symptomatic and asymptomatic patients in relation to response to
combined treatment. Although only eight symptomatic patients were
evaluated, the results obtained corroborated with those using the
combined therapy for patients with vasculitis5,6,22,37. As reported in the
literature, the majority of patients with RVS reduces or eliminates
cryoglobulins during the treatment, and in these cases, there are
improvements in the cutaneous lesions and renal disease, but not in
the neurological symptoms5,8,37.
More recently, in a pilot study with eighteen CHC patients with
MC, treated with pegylated interferon and ribavirin, found only 44%
of sustained virological response, what could suggest that this therapy
is not as effective as in patients with CHC without cryoglobulinemia23.
In conclusion, the study of cryoglobulins in 202 patients evaluated
consecutively showed a general prevalence of 27% and presence of
cryoglobulinemic syndrome with major symptoms in only 6% of the
cases. The prevalence was associated in an independent manner to the
presence of hepatic cirrhosis and to the age of patients. Even though
the type III cryoglobulin was the most prevalent, the type III
cryoglobulin was associated more frequently to the presence of
symptoms. The presence of this complication did not interfere in the
response observed to the combined therapy of interferon alpha and
ribavirin.
RESUMO
Crioglobulinemia na hepatite crônica C: aspectos clínicos e
resposta ao tratamento com interferon alfa e ribavirina
INTRODUÇÃO: A crioglobulinemia mista (CM) representa
importante complicação extra-hepática da hepatite C. Nesse estudo
avaliamos sua prevelência em pacientes com hepatite C crônica (HCC)
e relacionamos sua presença com aspectos clínicos e resposta ao
tratamento com interferon alfa e ribavirina. CASUÍSTICA E
MÉTODOS: 202 pacientes consecutivos com HCC (136 com hepatite
crônica e 66 com cirrose) foram avaliados para a presença de CM. Os
crioprecipitados foram caracterizados por imunoeletroforese e
classificados de acordo com BROUET et al. RESULTADOS: A
prevalência de CM nessa população foi de 27% (54/202), e, desses,
24% (13/54) apresentaram manifestações clínicas maiores da doença.
Embora MC tipo III tenha sido a forma mais freqüentemente
encontrada, a doença sintomática foi mais comum entre os pacientes
com MC tipo II. A presença de cirrose (RR = 2,073; IC95% = 1,029 -
4,179; p = 0,041) e a idade do paciente (RR = 1,035; IC95% = 1,008 -
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1,062; p = 0,01) estiveram independentemente associadas à presença
de CM. Não houve associação entre a presença de CM e genótipo ou
carga viral do vírus C. No total, 102 pacientes foram tratados com
interferon alfa e ribavirina. Desses, 31 apresentavam CM. A resposta
virológica sustentada (em torno de 30%) não diferiu entre pacientes
com e sem CM (p = 0,971). CONCLUSÃO: CM é uma freqüente
complicação na HCC, especialmente em pacientes com idade avançada
e com cirrose hepática. Apenas 24% desses pacientes apresentam
manifestações clínicas da doença, sendo mais freqüentes entre
portadores de CM tipo II. A presença de crioglobulinemia não afetou a
resposta virológica ao tratamento com interferon alfa e ribavirina.
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